IceCure Medical (NASDAQ:ICCM – Get Free Report) and Adynxx (OTCMKTS:ADYX – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for IceCure Medical and Adynxx, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
IceCure Medical | 0 | 0 | 2 | 0 | 3.00 |
Adynxx | 0 | 0 | 0 | 0 | N/A |
IceCure Medical presently has a consensus target price of $2.70, suggesting a potential upside of 331.24%.
Valuation & Earnings
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
IceCure Medical | $3.34 million | 8.56 | -$14.65 million | ($0.33) | -1.90 |
Adynxx | N/A | N/A | N/A | N/A | N/A |
Adynxx has lower revenue, but higher earnings than IceCure Medical.
Institutional and Insider Ownership
0.6% of IceCure Medical shares are held by institutional investors. 2.4% of IceCure Medical shares are held by company insiders. Comparatively, 17.4% of Adynxx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
IceCure Medical has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Adynxx has a beta of 2.68, suggesting that its share price is 168% more volatile than the S&P 500.
Profitability
This table compares IceCure Medical and Adynxx’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
IceCure Medical | -410.22% | -111.27% | -81.41% |
Adynxx | N/A | N/A | N/A |
Summary
Adynxx beats IceCure Medical on 5 of the 8 factors compared between the two stocks.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
About Adynxx
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.